TCF3/HLF-rearrangement plays a role as a pioneer transcription factor in recruiting EP300 to drive MYC, and EP300 inhibition reduces TCF3/HLF-dependent gene expression and ALL growth [64]. The gene discussed is TCF3; the disease is acute lymphoblastic leukemia.